期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
基于适应性免疫探讨津力达颗粒联合胰岛素治疗2型糖尿病的临床疗效及安全性 被引量:7
1
作者 黄俊臣 丁世芹 王明阳 《世界中西医结合杂志》 2020年第11期2062-2066,共5页
目的探讨津力达颗粒联合胰岛素治疗2型糖尿病的临床疗效及安全性。方法选取2018年6月—2020年5月期间濮阳市中医医院内分泌糖尿病科收治的98例2型糖尿病患者,按随机数字表法分为对照组和治疗组,各49例。对照组给予胰岛素注射给药,治疗... 目的探讨津力达颗粒联合胰岛素治疗2型糖尿病的临床疗效及安全性。方法选取2018年6月—2020年5月期间濮阳市中医医院内分泌糖尿病科收治的98例2型糖尿病患者,按随机数字表法分为对照组和治疗组,各49例。对照组给予胰岛素注射给药,治疗组在对照组基础上给予津力达颗粒口服。比较两组患者的临床疗效、血糖指标:空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2 h plasma glucose,2 h PG)、糖化血红蛋白A1c(Hemoglobin A1c,Hb A1c)、不良反应、治疗后外周血CD4+、CD8+T淋巴细胞的表达、CD4+/CD8+比值及血清炎症因子肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素(Interleukin,IL)-2、白细胞介素-6水平的差异性。结果治疗后治疗组患者血糖指标FPG、2 h PG、Hb A1c水平均较对照组显著下降(P<0.01)。对照组的总有效率为77.55%(38/49),治疗组的总有效率为93.88%(46/49),治疗组总有效率明显高于对照组(P<0.01);对照组的总不良反应为22.45%(11/49),治疗组的总不良反应为6.12%(3/49),治疗组总不良反应较对照组较低(P>0.05);与对照组比较,治疗后治疗组患者外周血CD8+T细胞百分率降低,外周血CD4+细胞百分率、CD4+/CD8+比值升高(P<0.01);治疗后治疗组血清炎性因子TNF-α、IL-2、IL-6水平均较对照组下降(P<0.01)。结论津力达颗粒联合胰岛素治疗2型糖尿病患者,可通过降低胰岛炎症反应,提高机体免疫力,改善患者临床症状,不良反应小,安全性高,值得临床推广应用。 展开更多
关键词 津力达颗粒 胰岛素 2型糖尿病
下载PDF
Clinical outcomes of percutaneous coronary intervention for chronic total occlusion lesions in remote hospitals without on-site surgical support 被引量:4
2
作者 CHEN Shao-liang YE Fei +9 位作者 ZHANG Jun-jie LIN Song ZHU Zhong-sheng TIAN Nai-liang LIU Zhi-zhong SUN Xue-wen ZHANG Ai-ping CHEN Feng ding shi-qin CHEN Jack 《Chinese Medical Journal》 SCIE CAS CSCD 2009年第19期2278-2285,共8页
Background The safety of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) lesions in remote hospitals without surgical facilities remains unknown. This study aimed to evaluate three-year ... Background The safety of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) lesions in remote hospitals without surgical facilities remains unknown. This study aimed to evaluate three-year outcomes after CTO for PCI in ten centers around China where no on-site coronary artery bypass grafting (CABG) support was available. Methods A total of 152 patients from 10 Chinese hospitals without on-site surgical facilities were prospectively studied. Intra-procedural and in-hospital events were assessed. Angiographic follow-up was indexed eight months after the initial procedure. Clinical follow-up was extended to three years. The primary outcome was the rate of major adverse cardiac events (MACE), defined as cardiac death, myocardial infarction and target-vessel revascularization (TVR). Results The incidence of CTO was 7.9% in patients who underwent PCI, Successful recanalization was achieved in 132 patients (86.8%). Compared with patients in the PCI success group, patients with PCI procedural failure had longer lesion lengths ((42.32±22.08) mm vs (27.61±22.85) mm, P=0.023), a higher rate of perforation (25.0% vs 0, P=0.014), and a greater need for pericardial puncture. There were significant differences in MACE in-hospital and at one year and three years between the failure (10.0%, 30.0% and 35.0%) and the success (3.0%, 12.1% and 14.4%) groups (P=0.037, 0.034 and 0.040, respectively). These led to a significant decrease in the MACE-free survival rate at one and three years in the failure group, compared with the success group (P=0.031 and 0.023, respectively). Stump was the only predictor of recanalization success (HR 0.158, 95% Cl 0.041-0.612, P=0.008), whereas procedural failure (OR 13.023, 95% CI 6.67-13.69, P=0.002), incomplete revascularization (OR 9.71, 95% CI 2.93-5.59, P=0.005), and total stent length (OR 6.02, 95% Cl 1.55-11.93, P=0.027) were three independent predictors of MACE. Conclusions PCI for CTO was unsafe in remote hospitals without CABG facilities. Paying attention to coronary perforation is important for successful procedures. 展开更多
关键词 chronic total occlusion major adverse cardiac events coronary artery perforation
原文传递
Comparison of paclitaxal vs. sirolimus eluting stents with bio-degradable polymer for the treatment of coronary bifurcation lesions: subgroup analysis from DKCRUSH-I and DKCRUSH-II studies 被引量:1
3
作者 CHEN Shao-liang Gary Mintz +9 位作者 Teguh Santoso ZHANG Jun-jie YE Fei XU Ya-wei FU Qiang KAN Jing Chitprapai Paiboon ZHOU Yong ding shi-qin Tak W Kwan 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第19期3382-3387,共6页
Background The difference in clinical outcome between paclitaxal-eluting stents (PES) and sirolimus-eluting stents with bio-degradable polymer (SES-BDP) for bifurcation lesions remains unclear. The present study a... Background The difference in clinical outcome between paclitaxal-eluting stents (PES) and sirolimus-eluting stents with bio-degradable polymer (SES-BDP) for bifurcation lesions remains unclear. The present study aimed to investigate the one-year clinical outcome after DK crush stenting using PES (maxusTM) MS. SES-BDP (ExcelTM) from our database. Methods A total of 275 patients (90 from the DKCRUSH-I and 185 from the DKCRUSH-II study) were studied. The primary endpoint was the occurrence of major adverse cardiac events (MACE) at 12 months; including cardiac death, myocardial infarction (MI), or target vessel revascularization (TVR). The rate of binary restenosis and stent thrombosis served as secondary endpoints. Results At follow-up, minimal luminal diameter (MLD) in the Taxus group was (2.11+0.66) mm, with resultant increased target lesion revascularization (TLR) 12.2% and TVR 14.4%, significantly different from the Excel group; (2.47±0.56) mm, P 〈0.001, 3.2%, P=0.006, 4.9%, P=0.019, respectively. As a result there was a significant difference in MACE between the Taxus (20.0%) and Excel (10.3%, P=0.038) groups. Overall stent thrombosis was monitored in 11 patients (4.0%), with five in the Excel group (2.7%) and six in the Taxus group (6.7%). All stent thrombosis in the Excel group was classified as early, and all were defined as late in the Taxus group. Conclusion The Excel stent had lower rate of stent thrombosis, TLR, TVR, and composite MACE at 12-month after an indexed stenting procedure, compared to the Taxus stent. 展开更多
关键词 paclitaxal-eluting stent sirolimus-eluting stent bio-degradable polymer coronary bifurcation lesions
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部